Report Description Table of Contents How Large Is the Weight Management Devices Market and What Factors Are Driving Its Growth? The Global Weight Management Devices Market was valued at USD 165 million in 2025 and is projected to reach USD 348 million by 2032, expanding at a CAGR of 11.3% during 2026–2032, according to Strategic Market Research. Weight management devices are increasingly being incorporated into obesity-care pathways for patients seeking clinically supervised alternatives to conventional bariatric surgery. The addressable patient base remains substantial, with around 2.5 billion adults worldwide classified as overweight and approximately 890 million living with obesity. Rising obesity prevalence is increasing pressure on hospitals, bariatric clinics and gastroenterology centers to offer treatment options that can bridge the gap between lifestyle intervention, pharmacotherapy and major surgery. Commercial adoption is already visible across intragastric balloon platforms. Boston Scientific reported that more than 400,000 Apollo gastric balloons had been distributed globally as of May 2024, while the ORBERA system is available in more than 80 countries. ORBERA365 has surpassed 50,000 balloons distributed worldwide. Allurion has reported more than 200,000 balloon placements internationally, while Spatz Medical has recorded more than 160,000 implantations of its adjustable gastric balloon. These deployment levels indicate an established international procedure base rather than a market dependent primarily on clinical trials or early-stage adoption. Demand is shifting toward temporary, reversible and less-invasive interventions. Intragastric balloons provide a non-surgical route for reducing food intake, while endoscopic suturing platforms enable procedures such as endoscopic sleeve gastroplasty without conventional abdominal surgery. Wider availability of trained endoscopists, growth of dedicated endobariatric programs, stronger patient referrals and integration of device procedures into multidisciplinary obesity care are expanding the number of eligible treatment settings. Regulation will remain important to competitive positioning. The FDA regulates gastric balloons, gastric bands, endoscopic suturing systems and other physical weight-management technologies, while updated 2026 premarket guidance places greater emphasis on clinical evidence, bench testing and benefit-risk assessment. Suppliers with stronger safety data, physician training networks and scalable treatment programs are therefore likely to capture a larger share of future market growth. What Regulations and Standards Are Shaping the Weight Management Devices Market Across the U.S., Europe, Asia Pacific and Globally? The U.S. FDA’s March 2026 final guidance, “Medical Devices with Indications Associated with Weight Loss – Premarket Considerations,” raises the clinical and regulatory requirements for companies developing weight-loss and weight-management devices. The framework covers technologies such as gastric bands, intragastric balloons, endoscopic suturing systems, removable oral devices and ingested space-occupying products, with applicable products continuing to move through pathways including 510(k), De Novo and Premarket Approval (PMA). A major change is the stronger emphasis on demonstrating that weight-loss outcomes are attributable to the device itself. The FDA recommends controlled clinical studies, including sham or concurrent control groups receiving comparable lifestyle interventions. It also expects a substantial portion of pivotal clinical evidence to come from U.S. patients, increasing the importance of domestic trial infrastructure for manufacturers seeking U.S. commercialization. For device developers, these requirements are likely to increase clinical development costs, evidence-generation timelines and regulatory scrutiny, particularly for new technologies without established predicates. Companies with stronger clinical datasets, well-designed trials and established regulatory capabilities may gain an advantage as weaker or insufficiently validated products face greater barriers to market entry. The guidance also broadens the commercial relevance of regulatory compliance as weight-management technologies expand beyond traditional bariatric implants toward temporary, removable and digitally supported treatment systems. As device-based obesity care becomes more integrated with multidisciplinary treatment programs, regulatory evidence on sustained weight loss, safety and benefit-risk performance will increasingly influence product approvals, physician adoption and competitive positioning in the U.S. market. Which Weight Management Device Types Are Leading the Market and Why Is Demand Increasing? Intragastric balloons represented 45.4% of the market in 2025, equal to USD 74.9 million, and are estimated to expand at a CAGR of about 10.0% during 2026–2032. Demand is supported by patients seeking a temporary intervention without permanent modification of the stomach. For example, Boston Scientific markets ORBERA as a reversible gastric balloon used with supervised diet and behavior modification; the company states that the system is used in more than 80 countries and that more than 400,000 Apollo gastric balloons had been distributed worldwide as of May 2024. (bostonscientific.com) Endoscopic suturing and ESG systems held 42.3%, or USD 69.8 million, in 2025 and are estimated to grow at approximately 13.5%, making this the strongest share-gaining device category. Hospitals and gastroenterologists purchase these systems because ESG can reduce stomach capacity through therapeutic endoscopy without abdominal incisions. Commercial adoption is becoming easier as payer access improves; Boston Scientific reported that Elevance Health began U.S. coverage for ESG using its OverStitch system in December 2025. (news.bostonscientific.com) Adjustable gastric bands accounted for 7.0%, or USD 11.6 million, with an estimated CAGR of about 2.5%. Demand is comparatively mature because newer endoscopic and pharmaceutical alternatives have widened the treatment choice available to patients. The segment nevertheless retains clinical relevance where physicians and patients value an implanted solution whose restriction can be adjusted after placement. Lap-Band remains actively marketed as an adjustable and reversible laparoscopic weight-loss device. (lapband.com) Other dedicated weight-management devices represented 5.3%, or USD 8.7 million, and are estimated to grow at around 11.5%. Demand is moving toward products that reduce treatment burden or give physicians greater flexibility. Spatz Medical's current Spatz3 portfolio illustrates this direction through an adjustable gastric balloon that allows its volume to be changed during treatment, giving clinicians a way to respond to intolerance or weight-loss plateaus without immediately abandoning balloon therapy. (spatzmedical.com) Which End Users Are Driving Weight Management Devices Market Demand? Hospitals and health systems generated 44.0% of 2025 revenue, or USD 72.6 million, and are estimated to grow at around 10.5% through 2032. Their leadership comes from their ability to perform ESG, gastric balloon procedures and bariatric interventions within established endoscopy and surgical departments. Device purchases increase as hospitals add less-invasive obesity procedures alongside conventional bariatric surgery. Specialty bariatric and obesity clinics represented 31.0%, or USD 51.2 million, with an estimated CAGR of about 11.5%. These clinics are important buyers of gastric balloons and other procedure-based weight-management technologies because obesity treatment is their core service line. Allurion’s model, which combines balloon treatment with nutritional and digital support across multiple international markets, reflects the shift toward bundled treatment programmes rather than standalone device sales. Gastroenterology and endoscopy centers accounted for 18.0%, or USD 29.7 million, and are estimated to grow at about 13.0%, making them the fastest-growing end-user segment. Growth is tied mainly to the expansion of endoscopic obesity procedures such as endoscopic sleeve gastroplasty. Existing therapeutic endoscopy infrastructure allows these centers to add weight-management procedures without building a separate surgical platform. Other clinical providers held 7.0%, or USD 11.6 million, and are estimated to expand at around 9.0%. This segment includes selected ambulatory and physician-led facilities capable of performing device-based obesity procedures and providing follow-up care. Adoption remains concentrated among centers with sufficient procedure volumes and trained clinicians. How Large Is the Treatment Gap Supporting Growth in the Weight Management Devices Market? The strongest demand opportunity comes from the large number of clinically eligible patients who remain untreated. An analysis cited by the American Society for Metabolic and Bariatric Surgery in May 2026, covering nearly 20 million patients with severe obesity, found that GLP-1 prescriptions increased from fewer than 4,600 in 2018 to more than 1.4 million in 2025. Despite this rapid expansion, approximately 90%–95% of patients in the studied population still received no obesity treatment. Surgical utilization also remains small relative to the eligible population. Bariatric procedures in the dataset increased to almost 43,000 in 2023 before falling below 40,000 in both 2024 and 2025, even as pharmacological treatment expanded sharply. This leaves a sizeable group of patients between lifestyle management, long-term medication and major bariatric surgery. For weight-management device manufacturers, this untreated population represents the more relevant commercial opportunity than obesity prevalence alone. Intragastric balloons and endoscopic procedures can address patients who require greater intervention than lifestyle therapy but are unwilling, unsuitable or not yet ready for conventional surgery. Market growth will therefore depend increasingly on how effectively hospitals, gastroenterology centers and obesity clinics convert this untreated population into procedure-based care. Which Regions Are Driving Weight Management Devices Market Growth and Why? North America held 38.0% of the market in 2025, equal to USD 62.7 million, and is estimated to grow at about 10.7% CAGR. The United States accounted for USD 56.1 million, making it the largest national market. Growth is supported by established therapeutic-endoscopy capacity, expanding ESG reimbursement and continued product commercialization. Spatz Medical’s U.S. launch of the Spatz3 adjustable gastric balloon highlights ongoing supplier investment in procedure-based obesity treatment. Europe represented 29.0%, or USD 47.9 million, with an estimated CAGR of approximately 10.2%. Germany, the UK and France account for the largest country opportunities. The region benefits from established private obesity-treatment networks and broad commercial availability of intragastric balloon systems. Allurion’s presence across major European markets, including Germany, Spain, Italy and the UK, reflects the maturity of regional distribution and physician adoption. Asia Pacific accounted for 22.0%, or USD 36.3 million, and is projected to record the fastest regional CAGR at about 13.4%. China generated USD 9.5 million, Japan USD 7.0 million and India USD 5.5 million in 2025. The region remains less penetrated than North America and Europe, creating greater headroom for growth as therapeutic endoscopy and specialist obesity-treatment capacity expand. Latin America held 6.0%, or USD 9.9 million, with an estimated CAGR of 11.3%. Brazil represents the largest regional opportunity because of its established bariatric-care base and stronger concentration of specialist private providers capable of offering device-based obesity procedures. Middle East & Africa accounted for 5.0%, or USD 8.3 million, and is estimated to grow at about 12.1%. GCC markets lead regional demand because specialist private hospitals can support premium endoscopic obesity procedures, while adoption elsewhere remains limited by lower procedure availability and fewer trained centers. Which Companies Are Leading the Weight Management Devices Market and How Are They Competing? Boston Scientific has one of the broadest endobariatric positions through ORBERA, ORBERA365 and the OverStitch endoscopic suturing platform. Its advantage is portfolio breadth: the company can participate in both temporary balloon therapy and higher-value procedures such as endoscopic sleeve gastroplasty and revision. ORBERA365’s treatment duration of up to 12 months in approved markets also gives Boston Scientific exposure to longer-duration non-surgical obesity treatment. Allurion Technologies competes through a more integrated outpatient model. Its swallowable balloon is paired with digital monitoring, nutritional support and connected-care tools, allowing the company to position the product as a managed weight-loss programme rather than a standalone implant. This model is particularly suited to private obesity clinics and markets where patients favor non-surgical treatment with limited procedural burden. Spatz Medical differentiates through the Spatz3 Adjustable Gastric Balloon, which allows balloon volume to be modified during treatment. That adjustability addresses two commercial limitations of fixed-volume balloons: poor early tolerance and reduced satiety later in therapy. With more than 160,000 reported implantations across over 80 countries, Spatz has built a sizeable international procedure base around this feature. Medtimo competes in a narrower but distinct segment through the Lap-Band system. Unlike temporary balloons or endoscopic suturing, Lap-Band offers a surgically placed but adjustable and reversible restrictive option without permanent gastric resection. Its competitive position is therefore concentrated among bariatric surgeons and patients who want a durable device-based intervention while avoiding irreversible stomach alteration. The competitive divide is becoming clearer: Boston Scientific leads through portfolio breadth, Allurion through integrated outpatient care, Spatz through device adjustability, and Medtimo through reversible surgical restriction. Future share gains are likely to depend less on device price and more on which companies can increase procedure adoption, physician utilization and repeat patient flow within established obesity-treatment networks. How Are GLP-1 Therapies and Other Treatment Options Affecting the Weight Management Devices Market? GLP-1 therapies are becoming the most important competitive pressure on weight-management devices because they give more patients a non-procedural treatment option before considering balloons, ESG or bariatric surgery. WHO’s December 2025 guideline supporting GLP-1 medicines as part of comprehensive obesity care, together with broader reimbursement initiatives such as CMS’s BALANCE model and Medicare GLP-1 Bridge, is likely to increase pharmaceutical treatment uptake and delay some device procedures. The impact, however, is more likely to reshape patient selection than eliminate device demand. ASMBS data indicate that 90%–95% of severely obese patients in the studied population remained untreated, leaving a large pool of patients who may still move between medication, endobariatric procedures and surgery depending on response, tolerance, cost and treatment preference. For device manufacturers, the strongest opportunity is therefore in patients who do not achieve sufficient results with medication, discontinue therapy, prefer a finite procedure-based intervention or want to avoid conventional bariatric surgery. ESG and intragastric balloons occupy this middle ground between pharmacotherapy and major surgery. Reaching the projected USD 348 million market size by 2032 will depend less on competing directly with GLP-1 drugs and more on establishing devices as a complementary treatment pathway within obesity care. Companies that can integrate device procedures with medication, nutritional support and structured follow-up are likely to be better positioned than suppliers selling a standalone procedure. What Factors Will Shape the Weight Management Devices Market Through 2032? Growth through 2032 will depend primarily on how quickly ESG and gastric balloon procedures move into routine obesity-care pathways. Hospitals and specialist clinics have a lower adoption barrier when these procedures can be added to existing therapeutic-endoscopy infrastructure rather than requiring a separate bariatric surgical programme. This favors suppliers whose systems are easier to introduce, require limited additional capital investment and can be supported through physician training. Reimbursement is likely to be one of the strongest volume triggers. Broader insurance coverage for ESG could shift the procedure from a largely self-pay service toward wider clinical use, while gastric balloon demand will remain more dependent on private-pay and specialist obesity networks in markets where coverage is limited. Product design will also influence competitive share. Swallowable balloons, adjustable systems and longer-duration devices reduce specific treatment barriers and give manufacturers clearer differentiation in a market where procedural convenience increasingly matters alongside efficacy. The main constraint is competition from GLP-1 therapies and bariatric surgery. Devices are unlikely to win by competing on weight-loss magnitude alone. Their strongest position is as an intermediate or complementary option for patients who do not respond adequately to medication, discontinue therapy, prefer a finite intervention or want to avoid conventional surgery. Suppliers that secure this role within integrated obesity-treatment pathways will be best positioned to capture growth through 2032. What Are the Latest Company Developments Directly Related to the Weight Management Devices Market? September 23, 2026 — Allurion Technologies: The U.S. FDA approved a revised post-approval study protocol for the Allurion Gastric Balloon System. The study is designed to continue evaluating safety and effectiveness in commercially treated patients following the system’s U.S. approval earlier in 2026. This is directly relevant to the Weight Management Devices Market because the Allurion Balloon is an FDA-approved intragastric weight-management device. FDA Access Data September 9, 2026 — Allurion Technologies: The FDA approved updated labeling for the Allurion Gastric Balloon System, including revisions to physician labeling, patient labeling and the patient information card to strengthen safety information. This followed the system’s original U.S. PMA approval on February 20, 2026. FDA Access Data August 2026 — Nitinotes: Nitinotes launched a USD 25 million Series C financing round to expand commercialization of its EndoZip automated ESG suturing system in Europe, complete its U.S. pivotal programme and scale manufacturing. The company states that EndoZip was already revenue-generating in Europe following its CE Mark and 2026 commercial launch. Because EndoZip is specifically designed for endoscopic sleeve gastroplasty, this investment directly supports expansion of the endoscopic weight-management device segment. Nitinotes Surgical June 29, 2026 — Nitinotes: The company expanded commercial adoption of EndoZip into France, with the first commercial procedures performed at IHU Strasbourg. This followed its initial 2026 European commercialization and demonstrates movement from clinical validation into real commercial ESG procedures. Nitinotes Surgical April 23, 2026 — Nitinotes: The first commercial EndoZip procedures in Spain were completed at Madrid Sanchinarro University Hospital. EndoZip is the first CE-marked automated suturing system specifically designed for endoscopic sleeve gastroplasty, making this one of the clearest 2026 product-commercialization developments in the Weight Management Devices Market. Nitinotes Surgical February 20, 2026 — Allurion Technologies: The FDA granted Premarket Approval to the Allurion Gastric Balloon System for adults aged 22–65 with BMI of 30–40 who had previously made at least one unsuccessful weight-loss attempt. The FDA-approved system can use up to two balloons during a 10-month treatment period and is intended to be combined with lifestyle-modification therapy. This gave Allurion direct entry into the U.S. regulated weight-management device market. FDA Access Data February 4, 2026 — Boston Scientific: Boston Scientific reported that Elevance Health coverage for endoscopic sleeve gastroplasty using the OverStitch Endoscopic Suturing System became effective December 18, 2025. Wider payer coverage improves patient access to ESG and strengthens the commercial case for hospitals and gastroenterology practices to adopt OverStitch-based weight-management procedures. Boston Scientific 2026 — Allurion Technologies: Allurion continues to commercialize its gastric-balloon-based weight-management programme internationally. Its current company materials report 200,000 patients treated internationally, showing established commercial utilization of the balloon platform rather than an early-stage pilot market. Allurion 2026 — Spatz Medical: Spatz Medical continues the U.S. commercialization of the Spatz3 Adjustable Gastric Balloon, which it launched in the United States in 2024 following FDA approval. Its current U.S. clinic network covers numerous states, including California, Florida, New York, Texas, New Jersey and Massachusetts, indicating an expanding commercial treatment footprint for adjustable intragastric balloons. Report Coverage Table Report Attribute Details Forecast Period 2026–2032 Market Size Value in 2025 USD 165 Million Revenue Forecast in 2032 USD 348 Million Overall Growth Rate CAGR of 11.3% (2026–2032) Base Year for Estimation 2025 Historical Data 2019–2024 Unit USD Million, Units/Procedure-Equivalent Device Units, CAGR (2026–2032) Segmentation By Device Type, By End User, By Geography By Device Type Intragastric Balloons, Endoscopic Suturing & ESG Systems, Adjustable Gastric Bands, Other Dedicated Weight-Management Devices By End User Hospitals & Health Systems, Specialty Bariatric & Obesity Clinics, Gastroenterology & Endoscopy Centers, Other Clinical Providers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, GCC Countries, South Africa Market Drivers Rising adoption of less-invasive and reversible obesity-treatment procedures; expansion of endoscopic sleeve gastroplasty and bariatric endoscopy; increasing use of intragastric balloons; growth of dedicated obesity and gastroenterology treatment centers; large untreated obesity population; improving procedure access and reimbursement; expansion of multidisciplinary obesity-care pathways Market Opportunities Expansion of ESG and endoscopic suturing procedures, swallowable and adjustable gastric balloons, connected patient monitoring, integrated device-plus-digital weight-management programs, and growth of specialist obesity treatment capacity in underpenetrated markets Key Market Constraints Growing competition from GLP-1 therapies, uneven reimbursement for endoscopic procedures, physician-training requirements, regulatory evidence requirements, and limited procedural availability in emerging healthcare markets Customization Option Available upon request Frequently Asked Question About This Report Q1. What is the size and growth outlook of the global Weight Management Devices Market? A1. The global Weight Management Devices Market was valued at USD 165 million in 2025 and is projected to reach USD 348 million by 2032. The market is expected to grow at a CAGR of 11.3% during 2026–2032. Q2. How many weight management devices are sold globally each year? A2. Global sales volume was estimated at approximately 156,500 devices and procedure-equivalent units in 2025. This includes intragastric balloons, endoscopic suturing and ESG procedure kits, adjustable gastric bands, and other dedicated clinical weight-management devices. Q3. Which device type holds the largest share of the Weight Management Devices Market? A3. Intragastric balloons hold the largest share, accounting for 45.4% of the market and generating approximately USD 74.9 million in 2025. The segment also represented the largest physical volume, supported by temporary placement, reversibility, and broad use across obesity-treatment clinics. Q4. Which weight management device segment is growing the fastest? A4. Endoscopic suturing and ESG systems are the fastest-growing major commercial segment, with an estimated CAGR of about 13.5% during 2026–2032. The segment generated approximately USD 69.8 million in 2025 as hospitals and gastroenterology centers expanded incisionless obesity procedures such as endoscopic sleeve gastroplasty. Q5. Which end users account for the largest demand for weight management devices? A5. Hospitals and health systems are the largest end users, accounting for 44.0% of 2025 revenue, or approximately USD 72.6 million. Specialty bariatric and obesity clinics represented 31.0%, while gastroenterology and endoscopy centers accounted for 18.0%. Q6. Which regions and countries represent the largest Weight Management Devices Markets? A6. North America led the global market with a 38.0% share and USD 62.7 million in 2025, with the United States contributing approximately USD 56.1 million. Europe followed with 29.0% and USD 47.9 million, while Asia Pacific accounted for 22.0% and USD 36.3 million and is expected to record the fastest regional growth. Sources Used in the Weight Management Devices Market Research Description Government, Regulatory and Public Health Sources U.S. Food and Drug Administration (FDA) — Weight-Loss and Weight-Management Devices Used for current FDA-recognized weight-loss device categories, gastric balloons, gastric bands, weight-management devices, safety considerations, and regulatory scope. FDA – Weight-Loss and Weight-Management Devices U.S. FDA — Medical Devices with Indications Associated with Weight Loss: Premarket Considerations, March 2026 Used for the 2026 regulatory discussion covering non-clinical testing, clinical-study design, benefit-risk assessment, PMA, 510(k), De Novo, and other premarket requirements. FDA – 2026 Weight-Loss Device Premarket Guidance U.S. FDA — Allurion Gastric Balloon System PMA P250023 Used to validate the February 20, 2026 U.S. approval of the Allurion Gastric Balloon System, its indication, patient eligibility, and treatment configuration. FDA – Allurion Gastric Balloon PMA U.S. FDA — Allurion Gastric Balloon PMA Supplement S001 Used for the September 9, 2026 labeling update covering physician labeling, patient labeling, and patient safety information. FDA – Allurion PMA Supplement S001 World Health Organization (WHO) — Obesity and Overweight Used for the global obesity treatment pool, including 2.5 billion overweight adults, more than 890 million adults living with obesity, and global prevalence trends. WHO – Obesity and Overweight U.S. CDC / National Center for Health Statistics — U.S. Adult Obesity Prevalence Used for U.S. obesity and severe-obesity prevalence, including the 40.3% adult obesity rate reported for August 2021–August 2023. CDC/NCHS – U.S. Obesity and Severe Obesity Prevalence Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge Used to assess how greater access to GLP-1 therapies could influence patient movement between pharmacological and procedure-based obesity treatment. CMS – Medicare GLP-1 Bridge CMS — BALANCE Model Used for analysis of evolving public reimbursement and access to obesity pharmacotherapy and lifestyle treatment. CMS – BALANCE Model European Commission — Medical Device Regulation Overview Used for European medical-device regulation, Regulation (EU) 2017/745, clinical-evidence requirements, conformity assessment, and market-access considerations. European Commission – Medical Device Regulations Therapeutic Goods Administration (TGA), Australia — Medical Device Inclusion Process Used for Australian medical-device market authorization and Australian Register of Therapeutic Goods requirements. TGA – Medical Device Inclusion Process International Organization for Standardization — ISO 13485 Used for medical-device quality-management-system requirements relevant to manufacturers and suppliers. ISO – ISO 13485 Medical Devices Clinical Associations and Healthcare Institutions Johns Hopkins Medicine — Endoscopic Options for Weight Loss Used to explain how gastric balloons and endoscopic sleeve gastroplasty fit between medication and conventional bariatric surgery, along with clinical workflow and reimbursement considerations. Johns Hopkins – Endoscopic Options for Weight Loss American Society for Metabolic and Bariatric Surgery (ASMBS) — Obesity Treatment Utilization Used for the 2026 analysis of nearly 20 million patients with severe obesity, GLP-1 prescription growth, bariatric procedure trends, and the finding that more than 90% of patients remained untreated. ASMBS – GLP-1 Use, Bariatric Surgery and Untreated Obesity Companies and Active Weight Management Device Suppliers Boston Scientific — ORBERA / ORBERA365 Intragastric Balloon System Used for product positioning, international availability, treatment duration, and the disclosure that more than 400,000 Apollo gastric balloons had been distributed worldwide as of May 2024. Boston Scientific – ORBERA365 Intragastric Balloon Boston Scientific — OverStitch NXT Endoscopic Suturing System Used for ESG and TORe applications, endoscopic suturing workflow, physician-training requirements, and competitive positioning in endobariatric procedures. Boston Scientific – OverStitch NXT Allurion Technologies — Allurion Gastric Balloon Program Used for current product positioning, international commercial reach, and the disclosure of more than 200,000 patients treated internationally. Allurion – Gastric Balloon and Weight Management Program Allurion Technologies — Healthcare Professional Program Used for clinic deployment, outpatient treatment workflow, multidisciplinary patient support, Connected Scale, Virtual Care Suite, and remote monitoring. Allurion – Healthcare Professionals Spatz Medical — Spatz3 Adjustable Gastric Balloon Used for adjustable gastric-balloon technology, international commercial presence, and the company's reported 160,000+ worldwide implantations across 80+ countries. Spatz Medical – Spatz3 Adjustable Gastric Balloon Medtimo — Bariatric Portfolio / LAP-BAND Used to verify the current LAP-BAND portfolio and commercial positioning of adjustable gastric banding. Medtimo – Bariatric Products Endo Tools Therapeutics — endomina Platform Used for endoscopic gastroplasty technology, current European clinical use, and active commercial development of incisionless gastric suturing systems. Endo Tools Therapeutics – endomina Endo Tools Therapeutics — July 2026 Series C Financing Used for the company's USD 23 million financing and planned U.S., European, and Middle Eastern commercialization of the endomina platform. Endo Tools Therapeutics – July 2026 Series C Financing Nitinotes Surgical — EndoZip Used for 2026 commercialization developments involving the automated endoscopic sleeve gastroplasty suturing platform and European procedure expansion. Nitinotes Surgical – News and EndoZip Developments Table of Contents - Global Weight Management Devices Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Device Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Summary of Market Segmentation by Device Type, End User, and Region Weight Management Treatment Gap and Procedure Adoption Outlook Market Share Analysis Leading Weight Management Device Manufacturers by Market Position Market Share Analysis by Device Type and End User Regional and Country-Level Weight Management Devices Market Share Analysis Intragastric Balloon versus Endoscopic Suturing and ESG Market Positioning Investment Opportunities in the Weight Management Devices Market High-Growth Opportunities in Endoscopic Sleeve Gastroplasty and Endoscopic Suturing Systems Investment Opportunities in Intragastric Balloon Platforms Emerging Opportunities in Adjustable, Swallowable, and Longer-Duration Gastric Devices Opportunities in Gastroenterology and Endoscopy Centers Digital Monitoring, Connected Care, and Post-Procedure Patient Management Opportunities Commercial Opportunities Across North America, Europe, and High-Growth Asia-Pacific Markets Market Introduction Definition and Scope of the Study Clinical Weight Management Device Classification Role of Weight Management Devices Between Pharmacotherapy and Bariatric Surgery Patient Selection and Weight Management Treatment Pathway Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Procedure-Led Device Consumption Assessment Manufacturer Shipment and Commercial Deployment Reconciliation Market Size and Sales Volume Estimation and Forecasting Techniques Manufacturer-Level Average Selling Price Assessment Device-Level Revenue and Procedure-Equivalent Unit Analysis Data Triangulation and Segment-Level Forecasting Approach Country-Level Revenue, Sales Volume, Product Mix, and ASP Assessment Market Dynamics Key Market Drivers Growth of Less-Invasive and Reversible Obesity Treatment Expansion of Endoscopic Sleeve Gastroplasty and Bariatric Endoscopy Growth of Intragastric Balloon-Based Weight Management Programmes Increasing Role of Gastroenterologists in Procedural Obesity Treatment Expansion of Specialty Bariatric and Obesity Clinics Untreated Obesity Population and Weight Management Treatment Gap Impact of Physician Training and Endoscopy Infrastructure on Device Adoption Impact of Insurance Coverage and Reimbursement on Procedure Volumes Competitive Pressure from GLP-1 and Other Anti-Obesity Therapies Opportunities for Combined Device, Pharmacotherapy, Nutrition, and Digital Care Regulatory and Standards Landscape U.S. FDA Weight-Loss and Weight-Management Device Requirements 2026 FDA Premarket Considerations for Weight-Loss Devices 510(k), De Novo, and Premarket Approval Pathways Clinical Evidence and Benefit-Risk Requirements for Weight Management Devices European Medical Device Regulation and CE Mark Requirements Asia-Pacific Medical Device Registration and Market Access Requirements ISO Quality Management, Risk Management, and Post-Market Surveillance Requirements Global Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Revenue Growth versus Procedure-Equivalent Sales Volume Growth Analysis Weighted Average Selling Price Analysis Market Analysis by Device Type: Intragastric Balloons Endoscopic Suturing & ESG Systems Adjustable Gastric Bands Other Dedicated Weight-Management Devices Market Analysis by End User: Hospitals & Health Systems Specialty Bariatric & Obesity Clinics Gastroenterology & Endoscopy Centers Other Clinical Providers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Weight Management Device Sales Volume and ASP Analysis Global Weight Management Device Sales Volume Analysis Intragastric Balloon Unit Sales Analysis Endoscopic Suturing and ESG Procedure-Equivalent Unit Analysis Adjustable Gastric Band Unit Sales Analysis Other Dedicated Weight-Management Device Unit Analysis Manufacturer-Level Average Selling Price by Device Type Regional and Country-Level Weighted ASP Analysis Relationship Between Device Mix, Procedure Volume, ASP, and Market Revenue Weight Management Treatment Pathway and Procedure Analysis Lifestyle Intervention and Behavioral Weight Management Pharmacotherapy and GLP-1 Treatment Intragastric Balloon Treatment Endoscopic Sleeve Gastroplasty Adjustable Gastric Banding Conventional Bariatric Surgery Patient Movement Between Medication, Endoscopic Procedures, and Surgery Connected Weight Management and Digital Care Ecosystem Connected Body Composition Scales and Remote Patient Monitoring Body Fat, Muscle Mass, Visceral Fat, and Metabolic Tracking Nutrition and Behavioral Weight Management Applications Integration of Connected Scales with Clinical Weight Management Programmes Remote Monitoring and Post-Procedure Patient Engagement Role of Hume Health, Withings, Noom, WeightWatchers, Cronometer, and Lose It! Core Clinical Device Market versus Adjacent Consumer Weight Management Ecosystem GLP-1 Therapies and Competitive Treatment Analysis Impact of GLP-1 Adoption on Weight Management Device Procedures Pharmacotherapy versus Intragastric Balloon Treatment Pharmacotherapy versus Endoscopic Sleeve Gastroplasty Role of Devices for Patients Discontinuing or Not Responding to Medication Combination of Weight Management Devices with Pharmacotherapy Impact of Medicare GLP-1 Access and Reimbursement Expansion Long-Term Positioning of Devices Between Medication and Bariatric Surgery Weight Management Devices Value Chain and Commercial Pathway Analysis Medical Device Component and Material Suppliers Weight Management Device Manufacturers Direct Sales and Medical Device Distribution Networks Hospitals, Bariatric Clinics, and Endoscopy Centers Gastroenterologists, Bariatric Surgeons, and Obesity Specialists Patient Treatment, Follow-Up, Nutrition, and Behavioral Support Recurring Procedure Consumables and Post-Treatment Monitoring Regional Market Analysis North America Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Market Analysis by Device Type and End User ESG Adoption, Gastric Balloon Commercialization, and Procedure Reimbursement Analysis Country-Level Weighted ASP and Procedure-Equivalent Volume Analysis Country-Level Breakdown: United States Canada Mexico Europe Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Market Analysis by Device Type and End User Gastric Balloon Adoption, Bariatric Endoscopy, and ESG Commercialization Analysis Medical Device Regulation, Reimbursement, and Country-Level Procedure Access Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Market Analysis by Device Type and End User Private Obesity-Care Expansion and Therapeutic Endoscopy Capacity Analysis Country-Level Device Mix, Weighted ASP, and Procedure Volume Analysis Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Market Analysis by Device Type and End User Bariatric Care Infrastructure, Private-Pay Treatment, and Gastric Balloon Demand Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Weight Management Devices Market Analysis Historical Market Size and Sales Volume (2019–2024) Base Year Market Size and Sales Volume Analysis (2025) Market Size and Sales Volume Forecasts (2026–2032) Market Analysis by Device Type and End User Private Hospital, Specialty Obesity Clinic, and Endoscopic Procedure Demand Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Weight Management Device Substitution and Treatment Competition Analysis GLP-1 and Other Anti-Obesity Drug Competition Conventional Bariatric Surgery Competition Intragastric Balloon versus ESG Treatment Positioning Adjustable Gastric Band versus Endoscopic Treatment Lifestyle and Behavioral Weight Management Alternatives Patient Preference, Treatment Duration, Reversibility, and Procedure Burden Application-Level Substitution Risk and Complementary Treatment Analysis Competitive Intelligence and Benchmarking Leading Key Players: Boston Scientific Corporation Allurion Technologies, Inc. Spatz Medical Medtimo Nitinotes Surgical Ltd. Endo Tools Therapeutics USGI Medical Competitive Landscape and Strategic Insights Benchmarking Based on Device Type, Procedure Workflow, Reversibility, Treatment Duration, and Physician Requirements Intragastric Balloon Portfolio Benchmarking Endoscopic Suturing and ESG Technology Benchmarking Adjustable Gastric Band Market Positioning Connected Care and Digital Patient Monitoring Benchmarking Regulatory Approval, Physician Training, Distribution, and Geographic Presence Benchmarking Recent Developments in the Weight Management Devices Market 2026 FDA Approval and Post-Approval Developments for the Allurion Gastric Balloon System Updated Allurion Gastric Balloon Physician and Patient Labeling Nitinotes EndoZip Commercialization and European Procedure Expansion Investment in Automated Endoscopic Sleeve Gastroplasty Systems Boston Scientific OverStitch ESG Coverage and Reimbursement Developments Spatz3 Adjustable Gastric Balloon U.S. Commercial Expansion New Endoscopic Weight Management Device Clinical and Commercial Developments Appendix Abbreviations and Terminologies Used in the Report Weight Management Device Definitions and Classification Procedure-Equivalent Unit Definitions Research Assumptions and Data Reconciliation Framework Market Scope, Revenue Boundary, and Exclusion Framework References and Sources List of Tables Global Weight Management Devices Market Size and Sales Volume (2019–2032) Market Size by Device Type, End User, and Region (2026–2032) Weight Management Device Sales Volume by Device Type (2026–2032) Manufacturer-Level Average Selling Price by Device Type Regional Market Breakdown by Device Type and End User (2026–2032) Major Country-Level Weight Management Device Revenue and Sales Volume (2026–2032) Country-Level Weighted Average Selling Price Analysis Competitive Benchmarking of Leading Weight Management Device Manufacturers Intragastric Balloon versus ESG versus Adjustable Gastric Band Comparison Weight Management Devices versus GLP-1 Therapy and Bariatric Surgery List of Figures Weight Management Devices Market Drivers, Opportunities, Competitive Pressures, and Constraints Global Weight Management Devices Market Revenue and Sales Volume Outlook (2025 vs. 2032) Weight Management Device Treatment Pathway from Lifestyle Intervention to Bariatric Surgery Market Share by Device Type and End User (2025 vs. 2032) Regional Weight Management Devices Market Snapshot Country-Level Weight Management Device Revenue and Sales Volume Comparison Weight Management Device Revenue Growth versus Physical Sales Volume Growth Global Weight Management Devices Value Chain and Commercial Ecosystem Competitive Landscape by Device Technology and Market Position Intragastric Balloon and Endoscopic Suturing Procedure Workflow GLP-1, Weight Management Device, and Bariatric Surgery Treatment Positioning Connected Monitoring and Digital Weight Management Ecosystem Growth Strategies Adopted by Leading Weight Management Device Manufacturers